CAR T-cell therapy tested for rheumatoid arthritis to eliminate disease-driving B cells

Inflammatory foci (magenta) are no longer detectable after the therapy. PIC COURTESY/Charite

Conventional rheumatoid arthritis drugs continuously suppress immunity rather than removing disease-driving B cells.

To treat refractory cases, Charite researchers are testing CD19-targeted CAR T-cell therapy an advanced immunotherapy that genetically modifies a patient's own immune T cells to recognise and destroy cancer cells.

Patients receive brief chemotherapy before a single infusion of genetically reprogrammed T cells, which eliminate harmful B cells in the body. This allows the immune system to rebuild without autoimmune memory.

This story has been sourced from a third party syndicated feed, agencies. Mid-day accepts no responsibility or liability for its dependability, trustworthiness, reliability and data of the text. Mid-day management/mid-day.com reserves the sole right to alter, delete or remove (without notice) the content in its absolute discretion for any reason whatsoever